Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (81-90 of 466) with videos related to

Pageof 47
Sort By:
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 26, 2006
Antagonizing inactivated tumor suppressor genes and activated oncogenes by a versatile transgenesis system: application in mantle cell lymphomaArmin Pscherer, Julia Schliwka, Kathrin Wildenberger, et al.
Haematologica|November 17, 2018
<i>TP53</i> aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnosticsElias Campo, Florence Cymbalista, Paolo Ghia, et al.
Blood|December 13, 2003
The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational statusPeter Dreger, Stephan Stilgenbauer, Axel Benner, et al.
Leukemia & Lymphoma|July 16, 2013
Extracellular vesicles in chronic lymphocytic leukemiaFranziska Haderk, Bola Hanna, Karsten Richter, et al.
Leukemia & Lymphoma|November 4, 2009
BCL2-938C>A polymorphism and disease progression in chronic lymphocytic leukemiaThorsten Zenz, Axel Benner, Ulrich Dührsen, et al.
Molecular and Clinical Oncology|December 15, 2021
Cost-effectiveness of precision cancer medicine-current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review)Konstantinos Christofyllakis, Joerg Thomas Bittenbring, Lorenz Thurner, et al.
Leukemia & Lymphoma|October 24, 2012
BRAF mutations in chronic lymphocytic leukemiaBilly Michael Chelliah Jebaraj, Dirk Kienle, Andreas Bühler, et al.
Blood|August 1, 2002
V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemiaAlexander Kröber, Till Seiler, Axel Benner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2004
Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation statusChristian Haslinger, Norbert Schweifer, Stephan Stilgenbauer, et al.
British Journal of Haematology|December 8, 2009
Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cellsIrina Idler, Krzysztof Giannopoulos, Thorsten Zenz, et al.
Pageof 47

Showing results (81-90 of 466) with videos related to

Sort By:
Pageof 47
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 26, 2006
Antagonizing inactivated tumor suppressor genes and activated oncogenes by a versatile transgenesis system: application in mantle cell lymphomaArmin Pscherer, Julia Schliwka, Kathrin Wildenberger, et al.
Haematologica|November 17, 2018
<i>TP53</i> aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnosticsElias Campo, Florence Cymbalista, Paolo Ghia, et al.
Blood|December 13, 2003
The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational statusPeter Dreger, Stephan Stilgenbauer, Axel Benner, et al.
Leukemia & Lymphoma|July 16, 2013
Extracellular vesicles in chronic lymphocytic leukemiaFranziska Haderk, Bola Hanna, Karsten Richter, et al.
Leukemia & Lymphoma|November 4, 2009
BCL2-938C>A polymorphism and disease progression in chronic lymphocytic leukemiaThorsten Zenz, Axel Benner, Ulrich Dührsen, et al.
Molecular and Clinical Oncology|December 15, 2021
Cost-effectiveness of precision cancer medicine-current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review)Konstantinos Christofyllakis, Joerg Thomas Bittenbring, Lorenz Thurner, et al.
Leukemia & Lymphoma|October 24, 2012
BRAF mutations in chronic lymphocytic leukemiaBilly Michael Chelliah Jebaraj, Dirk Kienle, Andreas Bühler, et al.
Blood|August 1, 2002
V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemiaAlexander Kröber, Till Seiler, Axel Benner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2004
Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation statusChristian Haslinger, Norbert Schweifer, Stephan Stilgenbauer, et al.
British Journal of Haematology|December 8, 2009
Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cellsIrina Idler, Krzysztof Giannopoulos, Thorsten Zenz, et al.
Pageof 47